Shire PLC (NASDAQ:SHPG) – Stock analysts at Jefferies Group decreased their FY2018 earnings estimates for Shire in a research report issued to clients and investors on Thursday. Jefferies Group analyst D. Steinberg now forecasts that the biopharmaceutical company will post earnings of $15.23 per share for the year, down from their previous estimate of $16.25. Jefferies Group also issued estimates for Shire’s Q4 2018 earnings at $3.78 EPS and FY2019 earnings at $16.48 EPS.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12. The business had revenue of $4.14 billion for the quarter. Shire had a net margin of 28.17% and a return on equity of 14.75%. Shire’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.37 EPS.
Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Royal Bank of Canada set a $192.00 price objective on shares of Shire and gave the stock a “buy” rating in a research note on Monday, February 5th. Bank of America raised their price objective on shares of Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a research note on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Shire currently has an average rating of “Buy” and an average price target of $204.00.
Shares of Shire (SHPG) traded down $7.39 during midday trading on Monday, hitting $126.67. 2,101,500 shares of the stock were exchanged, compared to its average volume of 1,506,449. The firm has a market cap of $39,140.00, a PE ratio of 9.19, a price-to-earnings-growth ratio of 0.75 and a beta of 1.41. Shire has a twelve month low of $123.73 and a twelve month high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
The business also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.8937 per share. This represents a dividend yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire’s previous semiannual dividend of $0.15. Shire’s payout ratio is currently 6.72%.
Several hedge funds and other institutional investors have recently bought and sold shares of SHPG. Harding Loevner LP raised its holdings in Shire by 18,894.4% in the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after buying an additional 126,865,607 shares during the period. Boston Partners raised its holdings in Shire by 60.9% in the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after buying an additional 886,572 shares during the period. Janus Henderson Group PLC raised its holdings in Shire by 35.3% in the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock valued at $266,613,000 after buying an additional 454,092 shares during the period. Ameriprise Financial Inc. raised its holdings in Shire by 6.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock valued at $245,997,000 after buying an additional 96,115 shares during the period. Finally, Third Point LLC purchased a new stake in Shire in the 3rd quarter valued at about $183,768,000. Institutional investors and hedge funds own 20.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group Brokers Cut Earnings Estimates for Shire PLC (SHPG)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/21/jefferies-group-brokers-cut-earnings-estimates-for-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.